Program
Pneumococcal 20-Valent Conjugate Vaccine
Also written as “20vPnC”, “20-valent pneumococcal conjugate vaccine” and “Prevnar 20”.
Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Respiratory Syncytial Virus Infections, led by 4 companies.
Drug pagePneumococcal 20-Valent Conjugate Vaccine: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 183 open or running | phase 3since Nov 29, 2018 | Nov 29, 2018 | Jun 10, 2027phase 1 · NCT07023081 |
| GlaxoSmithKline | 20 open or running | phase 3since May 18, 2023 | Jun 3, 2022 | none ahead |
| LiteVax BVits history only | 11 open or running | phase 1since Mar 30, 2025 | Mar 30, 2025 | none ahead |
| Merckits history only | 11 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | Oct 24, 2028phase 1 · NCT07300267 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 3, 2022First study: phase 2 study in Pneumonia, BacterialFirst studyNCT05412030 · 388 enrolled · United States, Puerto Rico
- May 18, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05879107 · 1,113 enrolled · United States, Belgium, Poland and more
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A pneumococcal conjugate vaccine containing 20 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 20-Valent Conjugate Vaccine”name, by rule
Studies
All 2 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05879107Respiratory Syncytial Virus Infections · United States, Belgium, Poland and more | 3 | Completed | Dec 6, 2023 | 1,113 |
| NCT05412030Pneumonia, Bacterial · United States, Puerto Rico | 2 | Completed | Sep 18, 2025 | 388 |
How it is read
Names in the registry
- “20vPnC”, 10 entries
- “20-valent pneumococcal conjugate vaccine”, 7 entries
- “Prevnar 20”, 2 entries
- “PCV20 (Stage 1)”, 1 entry
- “PCV20 (Stage 2)”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 18 studies
- Pneumonia, Pneumococcal, 1 study
- Respiratory Syncytial Virus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.